United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 309.57 USD 1.4% Market Closed
Market Cap: 14B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

UTHR Price Targets Summary
United Therapeutics Corp

Wall Street analysts forecast UTHR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for UTHR is 399.49 USD with a low forecast of 317.14 USD and a high forecast of 630 USD.

UTHR Lowest Forecast
Wall Street Target
317.14 USD
2% Upside
UTHR Average Forecast
Wall Street Target
399.49 USD
29% Upside
UTHR Highest Forecast
Wall Street Target
630 USD
104% Upside
Lowest
Price Target
317.14 USD
2% Upside
Average
Price Target
399.49 USD
29% Upside
Highest
Price Target
630 USD
104% Upside
United Therapeutics Corp Competitors:
Price Targets
MIRM
Mirum Pharmaceuticals Inc
49% Upside
IMAB
I-Mab
514% Upside
S
SANA
Sana Biotechnology Inc
364% Upside
BBIO
BridgeBio Pharma Inc
79% Upside
MIRM
Mirum Pharmaceuticals Inc
49% Upside
IMAB
I-Mab
514% Upside
S
SANA
Sana Biotechnology Inc
364% Upside
BBIO
BridgeBio Pharma Inc
79% Upside
BMRN
Biomarin Pharmaceutical Inc
63% Upside
Z
ZBIO
Zenas Biopharma Inc
187% Upside
BONEX
Bonesupport Holding AB
58% Upside
OPK
OPKO Health Inc
206% Upside

Revenue
Forecast

Revenue Estimate
United Therapeutics Corp

For the last 8 years the compound annual growth rate for United Therapeutics Corp's revenue is 8%. The projected CAGR for the next 3 years is 8%.

8%
Past Growth
8%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
United Therapeutics Corp

For the last 8 years the compound annual growth rate for United Therapeutics Corp's operating income is 4%. The projected CAGR for the next 3 years is 8%.

4%
Past Growth
8%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
United Therapeutics Corp

For the last 8 years the compound annual growth rate for United Therapeutics Corp's net income is 7%. The projected CAGR for the next 3 years is 3%.

7%
Past Growth
3%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

See Also

Summary
UTHR intrinsic value, competitors valuation, and company profile.
DCF Valuation
UTHR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
UTHR stock valuation using valuation multiples.
Wall Street Estimates
UTHR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
UTHR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is UTHR's stock price target?
Price Target
399.49 USD

According to Wall Street analysts, the average 1-year price target for UTHR is 399.49 USD with a low forecast of 317.14 USD and a high forecast of 630 USD.

What is United Therapeutics Corp's Revenue forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for United Therapeutics Corp's revenue is 8%. The projected CAGR for the next 3 years is 8%.

What is United Therapeutics Corp's Operating Income forecast?
Projected CAGR
8%

For the last 8 years the compound annual growth rate for United Therapeutics Corp's operating income is 4%. The projected CAGR for the next 3 years is 8%.

What is United Therapeutics Corp's Net Income forecast?
Projected CAGR
3%

For the last 8 years the compound annual growth rate for United Therapeutics Corp's net income is 7%. The projected CAGR for the next 3 years is 3%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 256,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.